PTGER2 and Osteopenia: To further elucidate the role of PGE2/EP2 in the development of muscle pathology and HO formation, we treated DKO-Hom mice at 4 weeks old (a time when significant muscle damage and osteopenia are observed) with the EP2 antagonist PF04418948 for two weeks.